🔎︎
The promise of brain-computer interfaces has long outpaced the regulatory machinery designed to evaluate them, and a detailed investigation published by STAT News reveals just how wide that gap remains for companies hoping to bring these devices to market.
Brain-computer interfaces, or BCIs, are implanted devices that detect neuronal activity and translate it into digital commands, enabling people with paralysis, ALS, and other neurodegenerative conditions to control robotic limbs, communicate via text, or interact with digital devices, using only their thoughts. Companies like Neuralink, Synchron, Blackrock Neurotech, Paradromics, and Precision Neuroscience have each conducted early human trials with encouraging safety profiles. What they have not yet established, at least to the FDA's satisfaction, is which clinical outcomes would demonstrate that the considerable risk of brain surgery is worth the benefit.
That is the central regulatory riddle. Unlike a continuous glucose monitor that measures time in range or a deep-brain stimulator that quantifies seizure reduction, BCIs don't treat an underlying condition; they provide a workaround. As Carnegie Mellon professor Doug Weber put it, the field must answer how to verify that a device is actually doing what the patient needs it to do. More than 100 potential metrics have been catalogued since a September 2024 FDA workshop, and the field has yet to reach consensus.
Neurologist Leigh Hochberg of Massachusetts General Hospital, a foundational figure in BCI research, has been pressing for robust clinical outcome assessments as a precondition for any meaningful pivotal trial. Researchers like Mount Sinai's David Putrino have proposed "critical digital activities," such as alerting a caregiver or controlling a feeding device, as a practical, measurable starting point that aligns with patient priorities and is more likely to win regulatory approval than flashier endpoints.
For managed care stakeholders, the regulatory outcome here carries downstream weight. A device approved with limited evidence of benefit and unclear long-term durability creates significant coverage ambiguity for CMS and commercial payers alike, a challenge the field has not yet addressed in earnest.
